Piramal Phytocare Limited Stock NSE India S.E.

Equities

PIRPHYTO

INE122J01015

Delayed NSE India S.E. 5-day change 1st Jan Change
- INR -.--% Intraday chart for Piramal Phytocare Limited -7.54% -.--%
Sales 2018 238M 2.86M Sales 2019 252M 3.02M Capitalization 941M 11.29M
Net income 2018 -225M -2.7M Net income 2019 -82M -984K EV / Sales 2018 4.58 x
Net cash position 2018 19.78M 237K Net Debt 2019 124M 1.48M EV / Sales 2019 4.23 x
P/E ratio 2018
-4.94 x
P/E ratio 2019
-11.4 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Piramal Enterprises Limited completed the acquisition of remaining 82.5% in Piramal Phytocare Limited. CI
Piramal Phytocare Limited Announces Resignation of Ankit Kotak as Chief Financial Officer CI
Piramal Phytocare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2019 CI
Piramal Phytocare Limited Reports Earnings Results for the First Quarter Ended June 30, 2019 CI
Piramal Phytocare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019 CI
Piramal Phytocare Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018 CI
Piramal Phytocare Limited Appoints Ankit Kotak as Chief Investor Relations Officer CI
Piramal Phytocare Limited Reports Earnings Results for the Second Quarter Ended September 30, 2018 CI
Piramal Phytocare Limited Announces Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2018 CI
Piramal Phytocare Limited Announces Chief Financial Officer Changes CI
Piramal Phytocare Limited Reports Standalone Audited Earnings Results for the Fourth Quarter and Year Ended March 31, 2018 CI
Piramal Enterprises Limited agreed to acquire remaining 82.5% in Piramal Phytocare Limited for approximately INR 740 million. CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017 CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2017 CI
Piramal Phytocare Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2017 CI
More news
Piramal Phytocare Limited, formerly Piramal Life Sciences Limited, is engaged in pharmaceutical business. The Company is engaged in the manufacturing and marketing of herbal products and other products. Its medicinal products are made from herbal extracts. It is engaged in global marketing of finished pharmaceutical dosage forms especially Proprietary Formulations, wherein the active ingredients are derived from natural sources. It offers a range of products that are developed to manage lifestyle ailments, such as diabetes, arthritis, obesity, constipation, liver damage, anxiety, sexual dysfunction, cough and cold. Its products include Sleecap capsule, Pylee capsule, Soyaklin forte capsule, Prementrid capsule, Zayata capsule, Rtunorm capsule, Khasceeze syrup, Intelimax capsule, Contudol gel, Phyleclip capsule, Contudol capsule, Sugarcare capsule, Stresscare capsule, Cardiocare capsule, Dormocare capsule, Femincare capsule and Menacare capsule. It is a part of the Piramal Group.
Sector
-
More about the company